Pregnancy outcomes and iron status in β-thalassemia major and intermedia: a systematic review and meta-analysis

Advancements in orally bioavailable iron chelators and MRI methods have improved life expectancy and reproductive potential in Thalassemia Major(TM) and Thalassemia Intermedia(TI). Pregnancy is associated with adverse maternal and neonatal outcomes, frequency of which has not been well delineated. This systematic review aimed to provide risk estimates of maternal and fetal outcomes in TM and TI and explore pregnancy's impact on iron homeostasis. Fifteen studies(429 participants,684 pregnancies) were included. Meta-analysis revealed a higher thrombosis risk in TI(3.7%) compared to TM(0.92%), unchanged from pre-pregnancy. Heart failure risks in the earlier years appeared similar(TM 1.6% vs. TI 1.1%), and maternal mortality in TM was 3.7%, but with current management, these risks are rare. Gestational diabetes and pre-eclampsia occurred in 3.9% and 11.3% of TM pregnancies. Caesarean section rates were 83.9% in TM and 67% in TI. No significant difference in stillbirth, small for gestational age neonates, or preterm birth incidence between TM and TI was observed. n TM pregnancies, red cell requirements significantly increased(from 102 to 139 ml/kg/year,p=0.001), and 70% of TI pregnancies required blood transfusions. As expected, increased transfusion alongside chelation cessation led to a significant increase in serum ferritin during pregnancy(TM(by 1005 ng/mL,TI by 332 ng/mL,p<0.0001). Deterioration in iron status was further reflected by an increase in liver iron concentration(from 4.6 to 11.9mg/g dry weight,p<0.0001) and myocardial T2* decrease(from 36.2 +/-2.5ms to 31.1ms) during pregnancy. These findings emphasize the elevated maternal risk of iron-related cardiomyopathy during pregnancy and labor, stressing the importance of cardiac monitoring and postpartum chelation therapy resumption.